Published in JAMA on June 08, 2011
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res (2012) 1.10
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 1.04
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs (2011) 1.00
Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Mol Diagn Ther (2015) 0.98
Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum (2013) 0.97
A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther (2013) 0.97
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
New vitamin D analogs as potential therapeutics in melanoma. Expert Rev Anticancer Ther (2012) 0.94
Genetics and epigenetics of the skin meet deep sequence. J Invest Dermatol (2012) 0.93
Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res (2011) 0.92
Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res (2012) 0.91
Updates in Therapy for Advanced Melanoma. Cancers (Basel) (2016) 0.91
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A (2013) 0.91
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med (2016) 0.90
NUAK2: an emerging acral melanoma oncogene. Oncotarget (2011) 0.90
Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90
Melanoma in 2011: a new paradigm tumor for drug development. Nat Rev Clin Oncol (2012) 0.89
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer (2013) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Update on primary head and neck mucosal melanoma. Head Neck (2015) 0.88
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol (2016) 0.88
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer (2011) 0.88
Targeted agents for the treatment of metastatic melanoma. Onco Targets Ther (2012) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Cutaneous Melanoma in Asians. Chonnam Med J (2016) 0.86
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res (2015) 0.85
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations. EJC Suppl (2013) 0.85
miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics (2013) 0.83
Molecular testing in melanoma. Cancer J (2012) 0.83
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
A brief history of melanoma: from mummies to mutations. Melanoma Res (2012) 0.83
Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One (2013) 0.82
Mucosal melanomas in the elderly: challenging cases and review of the literature. Clin Interv Aging (2014) 0.82
An emerging toolkit for targeted cancer therapies. Genome Res (2012) 0.81
Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol (2013) 0.81
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget (2016) 0.81
Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol (2014) 0.81
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther (2014) 0.81
Molecular targets in melanoma: time for 'ethnic personalization'. Expert Rev Anticancer Ther (2012) 0.80
Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer (2013) 0.80
The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol (2014) 0.80
Cutaneous melanoma: new advances in treatment. An Bras Dermatol (2014) 0.79
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. Am J Surg Pathol (2016) 0.79
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatol Ther (Heidelb) (2015) 0.78
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol (2012) 0.78
Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis. BMC Cancer (2015) 0.78
New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol (2013) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg (2012) 0.78
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging (2014) 0.78
Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med (2014) 0.77
Resistance to c-Kit inhibitors in melanoma: insights for future therapies. Oncoscience (2014) 0.77
SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol (2015) 0.77
Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. J Proteomics (2016) 0.77
Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med (2012) 0.77
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment Cell Melanoma Res (2016) 0.77
[Translational research and diagnostics of melanoma]. Pathologe (2012) 0.77
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer (2014) 0.76
Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr (2015) 0.76
Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer (2011) 0.76
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget (2015) 0.76
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. Ann Surg Oncol (2013) 0.76
The role of genetics in the pathogenesis of periocular cutaneous neoplasms: implications for targeted therapy. Semin Ophthalmol (2013) 0.75
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate. Chin J Cancer Res (2013) 0.75
The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer. J Genet Genomics (2015) 0.75
Evolving Therapeutic Strategies in Mucosal Melanoma Have Not Improved Survival Over Five Decades. Am Surg (2016) 0.75
Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts. Biomark Cancer (2015) 0.75
p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J (1987) 7.32
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer (2003) 4.68
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol (2006) 2.25
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Melanoma incidence and mortality among US whites, 1969-1999. JAMA (2002) 1.74
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res (2003) 1.44
Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development (2000) 1.43
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene (1993) 1.30
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer (2009) 1.30
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene (1996) 1.27
Loss of c-kit expression in cultured melanoma cells. Oncogene (1992) 1.26
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer (2003) 0.90
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res (2005) 2.64
Clinicopathological features of and risk factors for multiple primary melanomas. JAMA (2005) 2.62
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol (2005) 2.55
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48